Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.1K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.1K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

2.0K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.0K
Inhaled Medications01:23

Inhaled Medications

992
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
992
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.3K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.5K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.5K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

2.0K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-task deep learning for sub-clinical screening of mood and sleep disturbances using physical activity biomarkers.

Journal of affective disorders·2026
Same author

Effectiveness of Total Body Resistance Exercise Intervention on Sleep Quality Among Nursing Staff.

The journal of nursing research : JNR·2026
Same author

PoseShot: hybrid CNN-BiLSTM transformer model for free throw action recognition via pose analysis.

Scientific reports·2026
Same author

Risk of thyroid disorders after diagnosis of endometriosis: A 20-year retrospective cohort study.

Maturitas·2026
Same author

Inositol hexaphosphate alleviates ototoxicity and age-related hearing loss by preserving cochlear hair cells in mice.

British journal of pharmacology·2025
Same author

The Protective Effect of High-Pressure Ischemic Preconditioning on Rowing Performance During Consecutive 2000-m Efforts.

International journal of sports physiology and performance·2025

Related Experiment Video

Updated: Mar 29, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.7K

The use of corticosteroids in patients with COPD or asthma does not decrease lung squamous cell carcinoma.

Zhi-Hong Jian1, Jing-Yang Huang2, Frank Cheau-Feng Lin3,4

  • 1Department of Public Health and Institute of Public Health, Chung Shan Medical University, Taichung, Taiwan. s841039@yahoo.com.tw.

BMC Pulmonary Medicine
|December 5, 2015
PubMed
Summary
This summary is machine-generated.

Corticosteroid use in asthma and COPD patients did not reduce lung squamous cell carcinoma (SqCC) risk. A recent increase in corticosteroid dosage was significantly associated with an elevated SqCC risk, particularly in men.

More Related Videos

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.7K
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

10.7K

Related Experiment Videos

Last Updated: Mar 29, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.7K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.7K
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

10.7K

Area of Science:

  • Pulmonary Medicine
  • Oncology
  • Pharmacology

Background:

  • Asthma and COPD are linked to chronic airway inflammation and increased lung cancer risk.
  • Investigating the association between corticosteroid use and lung squamous cell carcinoma (SqCC) is crucial for patient management.

Purpose of the Study:

  • To evaluate the relationship between inhaled corticosteroid (ICS) and oral corticosteroid (OCS) use and the risk of developing SqCC.
  • To determine if corticosteroid therapy influences SqCC risk in patients with asthma or COPD.

Main Methods:

  • A nested case-control study design was employed.
  • Patients diagnosed with asthma or COPD between 2003-2010 were identified from a national health database.
  • SqCC cases were matched with four control individuals based on sex, age, and diagnosis date.

Main Results:

  • In men, high-dose ICS (OR 2.18) and low-dose ICS (OR 1.77) were associated with increased SqCC risk. High-dose OCS (OR 1.55) also showed an increased risk.
  • No significant association was found between cumulative ICS/OCS use and SqCC risk in women.
  • Recent increases in corticosteroid dosage, particularly high-dose ICS and OCS, were significantly linked to higher SqCC risk in men and women.

Conclusions:

  • Corticosteroid therapy does not appear to decrease SqCC risk in asthma and COPD patients.
  • Recent escalations in corticosteroid dosage represent a significant risk factor for SqCC development in this population.